MEDACorp launches Center for Pharmacoeconomics under Leerink Partners

MEDACorp, the expert network affiliate of healthcare investment bank Leerink Partners, launched a Center for Pharmacoeconomics on October 22, 2024 in Boston. The new division will produce commentaries, analyses, and resources on the long-term societal value of healthcare treatments in the United States, according to the announcement on PRNewswire.

Dr. Melanie Whittington has been appointed Managing Director and Head of the new division. The press release describes the unit's mission as being "the storyteller of healthcare innovation."

What the new division actually is

MEDACorp's existing business is a healthcare-focused expert network: physicians, scientists, payers, and former regulators made available for client calls, primers, and surveys. The CPE is a different shape. It is a content-producing arm that will publish analyses on pharmacoeconomic questions, the kind of work historically done by ICER (the Institute for Clinical and Economic Review), academic health-economics groups, and pharma companies' own HEOR (health economics and outcomes research) teams.

Whittington's profile fits that work. The release positions her as "a recognized leader in pharmacoeconomics," and the framing of the division's mission, evaluating societal impact rather than running calls, suggests CPE is meant to publish under its own banner.

Why an expert network builds this now

US drug pricing has been the dominant policy story for healthcare investors since the Inflation Reduction Act passed in August 2022. Medicare's negotiation list, the IRA's penalty structure for price hikes above inflation, and the 340B program disputes have all pushed pharmacoeconomics out of academic journals and into the daily workflow of healthcare analysts and PMs.

Buy-side clients evaluating pharma assets now need credible third-party views on what a treatment is worth, not just what it costs. ICER's reports move stocks. Pharma-funded HEOR studies are discounted by skeptical analysts. A research voice attached to a healthcare investment bank, separated from manufacturer payrolls, is a slot worth occupying.

Where this fits in the expert network competitive set

The major expert networks (GLG, Guidepoint, Third Bridge, AlphaSense/Tegus) have largely competed on roster size, moderator quality, and compliance infrastructure. Differentiation by published research is rarer. AlphaSense built its position partly on aggregating broker research alongside transcripts; Third Bridge publishes Forum interviews. MEDACorp's CPE looks closer to those moves: a content layer that lives alongside the call-based product.

The Leerink connection matters. Leerink is a healthcare-only sell-side shop, and MEDACorp serves buy-side clients across hedge funds, mutual funds, and PE. A pharmacoeconomics center under that umbrella will need to manage the obvious conflict question: how does CPE handle assets where Leerink has banking or research relationships? The release does not address this directly. Compliance protocols around the new division will matter for how seriously buy-side readers weight the output.

First CPE outputs and any disclosure framework will be the read on whether this is a research franchise or a marketing vehicle. The division is new enough that judgment should wait for the publications.